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Purpose: Oral capecitabine has been used as adjuvant therapy for colorectal cancer patients since the 1990s. Patient-initi-
ated cessation or reduced use of capecitabine occurs widely for various reasons, yet the consequences of these actions are 
unclear. The present study sought to clarify treatment outcomes in such patients. 
Methods: The study included 173 patients who had been diagnosed with stage II or III colon cancer according to the 
pathologic report after radical surgery at Samsung Medical Center from May 2005 to June 2007 and who had received 
capecitabine as adjuvant therapy. The patients were divided into groups according to whether the dose was reduced (I, 
dose maintenance; II, dose reduction) or stopped (A, cycle completion; B, cycle cessation). Recurrence and disease-free 
survival rates between the two groups each were analyzed. 
Results: Of the 173 patients, 128 (74.6%) experienced complications, most frequently hand-foot syndrome (n = 114). Re-
duction (n = 35) or cessation (n = 18) of medication was most commonly due to complications. Concerning reduced dos-
age, both groups displayed no statistically significant differences in recurrence rate and 3-year disease-free survival rate. 
Concerning discontinued medication use, the cycle completion group showed an improved recurrence rate (P = 0.048) 
and 3-year disease-free survival rate (P = 0.028). 
Conclusion: The results demonstrate that maintaining compliance with capecitabine as an adjuvant treatment for colon 
cancer to preventing complications positively affects patient prognosis.
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ological stage. Patients diagnosed with stage III based on path-
ological examination of biopsy specimens have a 67% 5-year 
survival rate. In patients with stage IV diagnosis, the 5-year 
survival rate is 30% if complete excision of metastastics lesions 
is executed [5]. There are different opinions on the principles 
of postoperative adjuvant chemotherapy. Stage II or III is often 
taken as an indication for adjuvant chemotherapy.
With the development of numerous anticancer drugs such 
as 5-FU, leucovorin, oxaliplatin, irinotecan, TS-1, and capeci-
tabine, adjuvant chemotherapy for colon cancer has been diver-
sified since the 1990s. From a clinical study presented in 2005, 
capecitabine in 1,987 patients with stage III colon cancer did 
not show inferior survival rate compared to 5-FU injection. 
Moreover, it showed fewer side effects than 5-FU [6-8]. Capeci-
tabine is an oral anticancer drug that is easy to take at home, 
that can eliminate difficulty in finding blood vessels and that 
can minimize the number of hospital visits.
Although capecitabine has less diarrhea, stomatitis, nausea, 
INTRODUCTION
Colon cancer is the second most common type of cancer world-
wide [1, 2]. About 1 million patients are diagnosed each year, 
and approximately half of them die of this disease. Also, about 
230 thousand patients who undergo colon cancer surgery re-
quire adjuvant chemotherapy [3, 4].
The most important prognostic factor of colon cancer is path-
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hair loss, and neutropenia than 5-FU with leucovorin, it causes 
more hand-foot syndrome [7]. Because of this complication, 
interruption of medication, depending on an individual’s com-
pliance, is frequent. In spite of this problem, little research has 
been done about whether reduced or interrupted medication 
affects the prognosis for the disease or not. Therefore, this re-
search was conducted to analyze the effect of dose reduction 
and interruption of postoperative adjuvant capecitabine on 
the oncological results of colon cancers.
METHODS
From May 2005 to June 2007, the number of patients prescribed 
with capecitabine as postoperative adjuvant chemotherapy for 
colon cancer at Samsung Hospital (Sungkyunkwan University 
School of Medicine) was 209. Among the patients, one hun-
dred seventy-three who underwent a radical resection, were 
diagnosed with stage II or III cancer, and were prescribed with 
capecitabine as adjuvant chemotherapy were enrolled as the 
subject group. Patients with rectal cancer or with a relapse dur-
ing medical treatment were excluded from the study. The final 
follow-up point was December 2009, and the average follow-
up period was 40 months (range, 30 to 55 months).
Capecitabine was used at 1,250 mg/m
2 twice a day for 14 days 
and was not administered for the next 7 days. This three-week 
period was considered as one cycle, and a total of 8 cycles was 
set as a standard. Depending on the stage of hand-food syn-
drome, patients with grade. I cancer were treated with mainte-
nance of dose and skin protection cream, and patients with 
grade II or higher cancer were treated with ointment, symp-
tomatic treatment, and reduction of capecitabine dose to 75% 
or interruption of medication, depending on the individual’s 
condition. Complications other than hand-foot syndrome, 
such as diarrhea, stomachache, stomatitis, or blood test abnor-
mality, were treated with either reduced dose or interruption 
of medication, depending on the practitioner’s decision. Cate-
gorization of each complication stages was done according to 
the National Cancer Institute of Canada Common Toxicity 
Criteria (NCIC) guideline.
One hundred seventy-three patients were categorized into 
the A group (medication cycle completed) or the B group (med-
ication interrupted), depending on whether the medication 
was interrupted or not. The patients were also categorized into 
group I (medicated with full dose) and group II (medicated 
with reduced dose), depending on the dosage of capecitabine. 
Medication interruption was defined as cases in which the first 
8-period cycle was not completed (medicated only 1 to 7 cycles). 
Clinical and pathological characteristics, the relapse rate, and 
the disease-free survival rate were analyzed in each group.
All the data were collected retrospectively through medical-
record analyses and phone interviews. PASW ver. 17.0 (SPSS 
Inc., Chicago, IL, USA) was used as the statistics program. The 
chi-square test was used for analyzing the data, and the Kaplan-
Meier method was used to analyze the relapse and the disease-
free survival rates. Statistical results were considered as signif-
icant when the P-value was less than 0.05.
RESULTS
Clinicopathological and relapse patterns
Among the 173 patients, 114 were male and 59 were female. 
The average age was 57.6 years (range, 29 to 78 years), 114 pa-
tients were younger than 65, and 59 patients were equal to or 
older than 65. Thirty-eight patients (22%) were in stage II, 
and 135 patients (78%) were in stage III. Fifty patients (28.9%) 
had a lesion on their right colon, and the other 123 patients 
(71.1%) had a lesion on their left colon. One hundred sixty 
patients (92.5%) had an adenocarcinoma, 11 patients (6.4%) 
had mucinous carcinoma, and 2 patients (1.1%) had a signet 
ring cell carcinoma. Fifty-five patients (31.8%) out of the 173 
had lymphatic or venous invasion, 96 patients (55.5%) did not 
have such invasion, and in 22 patients (12.7%), such invasion 
could not be verified.
During the postoperative follow-up period, physical examina-
tion, colonoscopy, CT scanning, and MRI scanning were done 
in order to find local relapses or remote metastases. Among the 
173 patients, twenty-one (12.1%) had a relapse during obser-
vation period. Nine of them (42.9%) had liver metastasis, 5 of 
them (22.8%) had a local relapse, 4 of them (19%) had lymph 
node metastasis, 2 of them (9.5%) had lung metastasis, and 2 
of them (9.5%) had peritoneal dissemination. Two patients 
(9.5%) died during the observation period.
Side effects of capecitabine
Among the 173 patients, 129 (74.6%) had side effects, and 
hand-foot syndrome was the most common at 65.9% (in 114 
Table 1. Treatment-related adverse events
a 
Complication No
Yes
Grage  
I, II
Grade  
II, IV
Undeter- 
mined
b
Hand-foot syndrome   59 (34.1)    84 (48.5)    18 (10.4)  12 (6.9)
Anorexia/nausea/vomiting 149 (86.1)  13 (7.5)    1 (0.6)  10 (5.8)
Laboratory abnormalities 159 (91.9)  14 (8.1) 0 (0) 0 (0)
Diarrhea 161 (93.1)    4 (2.3)    2 (1.2)    6 (3.5)
Stomatitis 162 (93.6)  11 (6.4) 0 (0) 0 (0)
Abdominal pain 168 (97.1) 0 (0) 0 (0)    5 (2.9)
Fatigue or asthenia 172 (99.4) 0 (0) 0 (0)    1 (0.6)
Alopecia 172 (99.4) 0 (0) 0 (0)    1 (0.6)
Values are presented as number (%).
aNational Cancer Institute of Canada Common Toxicity Criteria were used except 
for hand-foot syndrome; 
bThere is no specified description on the chart.Journal of the Korean Society of
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patients). Reduction or interruption of capecitabine medica-
tion was considered if the patient was in grade II or higher 
hand-foot syndrome. Forty-five (39.5%) among 114 patients 
were in grade II or higher hand-foot syndrome. Twenty-one 
(20.2%) among 129 patients with grade III or above had side 
effects (Table 1).
Cause of medication interruption or reduction
Among 46 patients with interrupted or reduced medication, 
35 (76.1%, group II) had reduced dosage (75%). In seven (15.2 
%) of those 35 patients the medication was eventually inter-
rupted, for a total of 18 patients (39.1%, group B) with inter-
rupted medication. Forty-two of the 46 patients (91.3%) had 
interrupted or reduced medication because of severe side ef-
fects, and the other 4 patients (8.7%) had interrupted medica-
tion because of poor compliance. Among the former 42 patients 
with interrupted or reduced dosage, 39 (92.9%) had hand-foot 
syndrome, 12 (28.6%) had nausea, 8 (19.0%) had diarrhea, 7 
(16.7%) had abnormal blood test results, 3 (7.1%) had neutro-
penia, 3 (7.1%) had hyperbilirubinemia, 4 (9.5%) had cheili-
tis, and 2 (4.8%) had stomachache.
Relapse and disease-free survival rates by dosage reduction
Patients without dosage reduction were in group I (n = 138, 
79.8%), and patients with reduced dosage were in group II (n = 
35, 20.2%), and there were no statistically significant differences 
in sex, location of lesion, pathological stages, and pathological 
characteristics, but group II has relatively older patients (P = 
0.048). There was no significant difference in relapse rate be-
tween the two groups (P = 0.144) (Table 2). The three-year 
disease-free survival rate of group I was 90.5%, and that of 
group II was 82.4%, but this difference was not statistically 
significant (P = 0.126) (Fig. 1).
Relapse and disease-free survival rates by medication 
interruption
Patients who had completed 8 cycles of medication were in 
group A (n = 155), and patients who had interrupted medica-
tion were in group B (n = 18). There were no statistically sig-
nificant differences in sex, age, location of lesion, pathological 
stages, pathological characteristics, and side effect occurrence 
(Table 3). However, the relapse rates of the two groups were 
10.3% and 27.8%, respectively, and this difference was statisti-
cally significant (P = 0.048). The three-year disease-free survival 
rates of the two groups were 90.7% and 70.9%, respectively, 
again this difference was statistically significant (P = 0.028) 
(Fig. 2).
Table 2. Characteristics of patients in Group I, dose maintenance, 
and Group II, dose reduction
Characteristics Group I (n=138) Group II (n=35) P-value
Sex
   Male
   Female
     92 (66.7)
     46 (33.3)
   22 (62.9)
   13 (37.1)
0.693
Age
   < 65
   ≥ 65
     96 (69.6)
     42 (30.4)
   18 (51.4)
   17 (48.6)
0.048
Location 
   Rt. colon
   Lt. colon
  40 (29)
  98 (71)
   10 (28.6)
   25 (71.4)
1.000
Stage
   II
   III
     31 (22.5)
   107 (77.5)
  7 (20)
28 (80)
0.823
Pathologic type
   Adeno carcinoma 
   Mucinous carcinoma/signet 
       ring cell carcinoma
127 (92)
11 (8)
   33 (94.3)
   2 (5.7)
1.000
Complication
   Yes
   No
     94 (68.1)
     44 (31.9)
  35 (100)
0 (0)
< 0.01
Recurrence
   Yes
   No
     14 (10.1)
   124 (89.9)
  7 (20)
28 (80)
0.144
Values are presented as number (%).
Rt. colon, from ascending to mid-transverse colon; Lt. colon, from distal transverse 
to sigmoid colon.
Table 3. Characteristics of patients in Group A, cycle completion, and 
Group B, cycle cessation 
Characteristics Group A (n=155) Group B (n=18) P-value
Sex
   Male
   Female
105 (67.7)
  50 (32.3)
  9 (50)
  9 (50)
0.188
Age
   < 65
   ≥ 65
105 (67.7)
  50 (32.3)
  9 (50)
  9 (50)
0.188
Location 
   Rt. colon
   Lt. colon
  42 (27.1)
113 (72.9)
     8 (44.4)
   10 (55.6)
0.168
Stage
   II
   III
  33 (21.3)
122 (78.7)
     5 (27.8)
   13 (72.2)
0.551
Pathologic type
   Adeno carcinoma 
   Mucinous carcinoma/signet
        ring cell carcinoma
142 (91.6)
13 (8.4)
  18 (100)
0 (0)
0.366 
Complication
   Yes
   No
113 (72.9)
  42 (27.1)
   16 (88.9)
     2 (11.1)
0.165
Recurrence
   Yes
   No
  16 (10.3)
139 (89.7)
     5 (27.8)
   13 (72.2)
0.048
Values are presented as number (%).
Rt. colon, from ascending to mid-transverse colon; Lt. colon, from distal transverse 
to sigmoid colon.Journal of the Korean Society of
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DISCUSSION
Capecitabine is a 5-FU prodrug which is converted into 5-FU 
by thymidine phosphorylase inside the cancer tissue. The con-
centration of thymidine phosphorylase in cancer cells is higher 
than that in normal cells; thus, cancer cells are affected more 
selectively [9]. The maximum concentration in the blood is 
reached in 1.5-2 hours when 1,250 mg/m
2 (standard amount) 
is taken [10, 11]. Capecitabine intake for postoperative adju-
vant purposes is known to be safer while having effects simi-
lar to those of other intravenous anticancer drugs [6-8]. The 
benefits of capecitabine are ease of oral administration, no 
need for reserved blood vessel, and home administration of 
the drug. Also, there are reports that it is less expensive than 
administrating 5-FU and other intravenous anticancer drugs 
[10, 12, 13]. However, there are disadvantages in capecitabine 
administration as well. First, it is difficult to monitor whether 
the patient is taking the drug in the right way because it is often 
administered at the patient’s home, and the result is greatly af-
fected by patient’s compliance. Second, although it has fewer 
occurrences of diarrhea, stomatitis, nausea, hair loss, and neu-
tropenia, it has more occurrences of hand-foot syndrome [7]. 
In cases involving the side effects of capecitabine where the 
dosage is reduced or medication is interrupted, there have been 
few discussions about how the reduction and/or interruption 
affects the prognosis. However, there are reports that in older 
patients with breast cancer, a lower dosage of capecitabine shows 
effects similar to those achieved with normal dosage [14, 15]. 
In addition, there has been a case study where a patient with 
stage IV gastric cancer had a reduced dosage because of severe 
hematological side effects, but was completely recovered [16]. 
However, reduced dosage in older patients with non-Hodgkin 
lymphoma resulted in relapse and exacerbation, which increas- 
ed mortality [17]. Since dosage reduction is done in older pa-
tients in order to reduce complications, further research is nec-
essary to establish the relation between prognosis and dose 
reduction.
This research was done with 173 colon cancer patients at Sam-
sung Medical Center who took capecitabine as a postoperative 
adjuvant treatment. It was done in order to see whether re-
duced dosage or interrupted medication affected the relapse 
rate and the prognosis. In cases where dosage was reduced, 
there were no statistically significant differences in the relapse 
rate and the disease-free survival rate. In cases where medica-
tion was interrupted completely, the relapse rate was higher, 
and the disease-free survival rate was lower. However, there 
are several disputes about whether the difference in the prog-
nosis was solely affect   ed by the reduced dosage or interrupted 
medication. First, the number of patients was relatively small, 
which caused a low number of relapsed patients and difficulty 
with subject group categorization. This research only separated 
the patients into two groups based on their medication period 
(8-cycle scompletion). Among these patients, there were 6 pa-
tients who took the drug for less than 4 cycles. There are no 
data about how capecitabine affects oncological change when 
administered for such a short period. Also, analysis of onco-
logical outcome based on detailed categorization of adminis-
tration period was difficult in this research, as was finding the 
relationship between reduced dosage and prognosis. Secondly, 
there are factors such as age, physical status, and compliance 
that can affect the oncological outcome and are difficult to an-
alyze. There were no clinicopathological differences between 
the interrupted medication group and the completed medica-
tion group. However, the reduced dosage group turned out to 
have older patients, an intrinsic error of the retrospective study. 
This might have affected the oncological results and the medi-
cation side effects. In the future, prospective data collection and 
analysis of various factors that can affect prognosis are neces-
sary. Lastly, a patient with short follow-up period (32 months) 
was included in the subject group. This patient might have had 
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a relapse if the follow-up had been longer, so the relapse rate 
and the disease-free survival rate might be underestimated.
Interrupted medication or reduced dosage was most common 
when complications occurred. One hundred twenty-nine (74.6 
%) out of 173 patients had complications, but other research 
has reported complications of 22-31% [6, 7]. The most com-
mon complication was hand-foot syndrome, for which the in-
cidence was 65.9% (114 patients), which is very high when 
compared with other reports (6%) [6, 7]. Stricter judgment 
and over measurement are thought to be the cause of this high 
frequency. There could have been error by prepossession of 
the researcher, and it was difficult to collect accurate data for 
patients without a detailed description. Also, the amount of 
capecitabine was based on accepted dosage for Westerners and 
could have been an overdose for Asians.
The most frequent cause of interrupted medication or reduced 
dosage was occurrence of complications. In case of cetuximab, 
there is a report that occurrence of skin disease is a prognos-
tic factor that contributes to patient’s outcome [18, 19]. While 
this situation might be true in the case of capecitabine, there 
are no reports on this topic. Accordingly, more research on 
the complications of capecitabine, which cause dosage reduc-
tion or interrupted medication and on the effects of reduction 
pr interruption of medication on the prognosis is needed.
Capecitabine is one of the drugs that can be used with ease 
in colon cancer patients for postoperative adjuvant purposes. 
The most common cause that induces interrupted medication 
or dosage reduction is development of complications. This re-
search suggests that interrupted medication affects the relapse 
rate whereas reduced dosage does not. Accordingly, minimiz-
ing the toxicity of the drugs and finishing the scheduled treat-
ment are thought to result in improved prognosis. Therefore, 
continuous treatment, prevention of complications, and active 
and systematic treatment are necessary.
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